Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its heterogeneity and limited treatment options.
• Chemotherapy remains the primary treatment, but novel strategies are urgently needed for improved patient outcomes.
• Recent advances in omic technologies have enhanced understanding of TNBC's cellular and immune microenvironment.

Purpose of the Study:

• To review prospective nanobiotherapies for triple-negative breast cancer.
• To discuss how novel nanoparticulate systems can overcome clinical obstacles in TNBC treatment.
• To provide insights into the future of TNBC biotherapy at the intersection of nanomedicine and cancer research.

Main Methods:

• Review of current literature on nanobiotherapy for TNBC.
• Analysis of emerging nanoparticulate systems, including tumor vaccines, oncolytic viruses, and antibody derivatives.
• Exploration of omic technology advancements in understanding TNBC pathology.

Main Results:

• Nanoparticulate systems show potential in addressing TNBC heterogeneity.
• Novel therapeutic approaches like tumor vaccines and oncolytic viruses are being developed.
• Understanding the tumor microenvironment is key to designing effective nanobiotherapies.

Conclusions:

• Nanobiotherapy represents a promising frontier for treating triple-negative breast cancer.
• Translating experimental nanomedicines into clinical practice requires addressing current challenges.
• The synergy between cancer biotherapy and nanomaterial design offers a hopeful outlook for TNBC patients.